Every Second Counts
1
Impact more lives with the most promising breakthrough therapies
2
Reduce financial and operational uncertainty
3
Accelerate the best and brightest translational research
Today, the high cost and lack of expertise at a majority of healthcare providers in the country, means that most cancer patients never receive the benefit of breakthrough therapies.
We overcome these barriers by enabling a network of world-class cancer centers and oncologists to provide the highest quality access to the most promising breakthrough cancer therapies.
Cancer care is at its most promising point in the last 25 years. Yet, the industry is witnessing what happens when the science becomes so promising; it outstrips our financial and operational ability to effectively implement these advances in the clinic. That is simply not an acceptable option for patients who can benefit from these new treatments and technologies.
New drug therapies, including immunotherapies — a treatment method that supercharges the body’s own immune system to fight cancer — have revolutionized cancer treatment in the US. These emerging therapies will become first line treatments for many cancers including lung cancer, melanoma and leukemia over the next five years, extending and enhancing the quality of life for cancer patients.
The cost and complexity of these new treatments force tremendous strain on health systems and payers, placing these therapies in the ultra-high cost drug category. This results in a growing number of patients unable to access these potentially life-saving treatments.